Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead candidate. Phase III clinical study ongoing for prevention of new basal cell carcinomas in adults with Gorlin Syndrome. Orphan Drug Designation and Breakthrough Therapy designation.
SGT-210
Stage not disclosed · ActiveModality: topical drug candidate
Aliases erlotinib
Target EGFR
Indications
not disclosed(Stage not disclosed)
Status note Topical erlotinib platform; development continuing. No stage or indication disclosed in 20-F.
Per-asset detail extracted from the 20-F filed 2026-03-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.